← Leaderboards
Denis Marc Daigle
Venatorx Pharmaceuticals, Inc.
$7,512,530
Attributed
$7,512,530
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2019–23$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$7,512,530 · 1
By mechanism
R01$7,512,530 · 1
Top collaborators
No co-investigators on record.
Most similar at Venatorx Pharmaceuticals, Inc.
Same institution · by research overlap
- Steven Armen Boyd$13,685,544
- Luigi Xerri$39,662,982
- Guo-Hua Chu$599,200
- Tsuyoshi Uehara$2,000,000
Others in their field
Other Emerging Leaders on “Cyclic Gmp”
- Leonard Freedman · Leidos Biomedical Research, Inc.$239,520,687
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,746,909
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$28,173,207
- Howard Tranter$12,180,851
- Richard Scranton · Lyndra Therapeutics, Inc.$12,106,230
Research focus
Cyclic GmpContractsCrystallizationAnalytical MethodAnti-Infective AgentsAnti-Bacterial AgentsAntibioticsBactericideAntigenic VariationBeta-LactamaseBeta-LactamsBindingAppropriate DoseCefiximeCeftriaxoneAzithromycinCephalosporin ResistanceCephalosporinsChlamydia TrachomatisClinical CandidateClinical DevelopmentClinically RelevantClinical ResearchDesign
Grant awards (5)
New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae$1,582,840
R01 · FY2023 · AI · contact PI
New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae$1,579,751
R01 · FY2022 · AI · contact PI
New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae$1,441,089
R01 · FY2021 · AI · contact PI
New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae$1,417,435
R01 · FY2020 · AI · contact PI
New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae$1,491,415
R01 · FY2019 · AI · contact PI